BRIEF RESEARCH REPORT article

Front. Plant Sci.

Sec. Plant Biotechnology

Volume 16 - 2025 | doi: 10.3389/fpls.2025.1605548

This article is part of the Research TopicPlant Molecular Farming for Biopharmaceutical Production and BeyondView all 7 articles

Engineering the moss Physcomitrium patens to produce proteins with paucimannosidic glycans

Provisionally accepted
Jessica  JonnerJessica JonnerBenjamin  FodeBenjamin FodeJonas  KochJonas KochSören  BollerSören BollerPaulina  Anna Dabrowska‐SchleppPaulina Anna Dabrowska‐SchleppAndreas  SchaafAndreas SchaafChristian  SievertChristian Sievert*
  • Eleva GmbH, Freiburg, Germany

The final, formatted version of the article will be published soon.

The moss Physcomitrium patens is an advantageous host for the production of biopharmaceutical proteins, particularly due to the ease of glyco-engineering. However, the ability to produce proteins with paucimannosidic (MM) glycans in this species currently depends solely on the nature of the product. MM glycans offer benefits for some therapeutic proteins by facilitating their import into target cells via a presumed mannose receptor. Here, we describe the use of Spodoptera frugiperda enzymes expressed in moss to produce recombinant human lysosomal acid α-glucosidase with mainly MM glycans. We tested the expression of mannosidase type III and a hexosaminidase by varying the promoter strength and protein localization. The parental line produced recombinant α-glucosidase with no detectable MM glycans at all, whereas the weak expression of mannosidase type III targeted to the medial Golgi produced 4% MM glycans. The strong expression of a hexosaminidase targeted to the extracellular space increased the MM glycan content to 43.5%. Unlike previous attempts to express proteins with MM glycans in plants, neither of our introduced modifications interfered with growth or recombinant protein production. Our data confirm that the finely tuned expression and cellular localization of the glycosylation machinery can improve the efficiency of glyco-engineering. We also exploit the assembly of DNA fragments in vivo, which overcomes the limitations of traditional knock-in methods and facilitates the screening of different genetic elements. Our combined methods therefore represent the first straightforward approach allowing the production of recombinant proteins with abundant MM glycans.

Keywords: paucimannosidic glycans, Glyco-engineering, Lysosomal acid α-glucosidase, Physcomitrium patens, Hexosaminidase

Received: 03 Apr 2025; Accepted: 05 Jun 2025.

Copyright: © 2025 Jonner, Fode, Koch, Boller, Dabrowska‐Schlepp, Schaaf and Sievert. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Christian Sievert, Eleva GmbH, Freiburg, Germany

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.